Bristol-Myers Squibb Earlier Announced Pooled Five-Year Results Showed Patients Treated With Opdivo (Nivolumab) Continued To Experience Long-Term Overall Survival (OS) Benefit Versus Docetaxel
Benzinga Newsdesk